Phase i and Randomized Phase II Study of Ruxolitinib with Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study
Charles N. Landen, Ronald J. Buckanovich, Michael W. Sill, Robert S. Mannel, Joan L. Walker, Paul A. Disilvestro, Cara A. Mathews, David G. Mutch, Marcia L. Hernandez, Lainie P. Martin, Erin Bishop, Sarah E. Gill, Mary E. Gordinier, Robert A. Burger, Carol Aghajanian, Joyce F. Liu, Kathleen N. Moore, Michael A. Bookman
Dive into the research topics of 'Phase i and Randomized Phase II Study of Ruxolitinib with Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study'. Together they form a unique fingerprint.